Utah-based Blackrock Neurotech has already microchipped at least 50 people – transhumanism in action

There are people in the United States who have already received brain implants from a Utah-based company called Blackrock Neurotech, which has unleashed a microchip called NeuroPort Array that allows people with physical disabilities to perform tasks using just their brains.

Headquartered in Salt Lake City, Blackrock Neurotech has branded this brain implant as a solution to “cure” physical paralysis, blindness, deafness, and even depression. Recipients of the chip can control robotic arms and wheelchairs, play videogames, and even feel sensations because of it.

Equipped with nearly 100 microneedles, NeuroPort Array is attached to the brain, where it reads electrical signals produced by a person’s thoughts. So far, around 50 people have opted to get one injected into their brains.

“We are the only company with direct-brain BCI implants in humans,” proudly announced Marcus Gerhardt, Blackrock’s co-founder.

“Our implantable arrays have enabled people to connect directly to computers, control robotic arms and wheelchairs, play video games, even regain sensation – with just their brain signals.”

(Related: Elon Musk is working on the very same type of thing with his Neuralink brain chip implants.)

Will implantable brain microchips eventually become mandatory?

NeuroPort Array can be placed anywhere on the brain’s surface, and multiple NeuroPort Arrays can exist on the same brain.

Machine learning software tracks and decodes the electrical signals generated by a wearer’s thoughts into digital commands such as cursor movements on a screen, which can then be used to control prosthetics, computer equipment, and more.

As with most implantable chips, the company behind NeuroPort Array is branding it as a medical device to help people in need. This is simply the cover story for normalizing chip implants into human bodies, which is ultimately leading to the Mark of the Beast and transhumanism.

Right now, NeuroPort Array is only being used in voluntary participants in the Blackrock lab. The company hopes to soon gain FDA approval for the devices to be commercialized across the entire population.

“We are pursuing regulatory approval of the world’s first-ever BCI designed specifically for at-home use: MoveAgain,” Gerhardt explained. “This medical device aims to increase independence and mobility, and ultimately, quality of life, for people with paralysis.”

“Once home-use BCIs are available, they’ll help people build new lives that may have seemed impossible following their disability; we think we’ll see people return to work, establish greater independence, and engage with the world in powerful new ways.”

There is a lot of money to be made from these microchips, and Blackrock’s goal is to maximize their use across the entire population.

“Our long-term vision is that our implants will become as readily available to people with paralysis as pacemakers are for people with heart issues,” Gerhardt added.

NeuroPort Array is already being customized for other uses such as to restore hearing and vision. Virtually any health condition is on the radar for NeuroPort Array to “fix,” the company has said.

“As the technology continues to advance, we’ll see BCIs with indications for memory and mental health conditions like anxiety and depression,” Gerhardt further revealed.

One major downfall with NeuroPort Array is that the device’s palisades, or arrays, break down over time, causing the signal to degrade. This means that the device has to be removed and replaced around every five years, which involves more surgeries.

The first implant occurred back in 2004, though the company did not reveal this publicly due to public perceptions about implantable microchips.

“The sky’s the limit for what BCIs will be able to do in the future,” Gerhardt added.

Just to be clear, Blackrock Neurotech is not related to the BlackRock asset management firm.

To learn more about these chip implant predecessors to the Mark of the Beast, visit Prophecy.news.

Sources for this article include:

DailyMail.co.uk

NaturalNews.com